Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Hagemann IS, Deng W, Zaino RJ, Powell MA, Gunderson Jackson C, Cosgrove C, Mathews C, Pearl ML, Waggoner S, Ghebre R, Lele S, Guntupalli S, Secord AA, Ioffe O, Rasty G, Singh M, Soslow R, Creasman W, Mutch DG. Hagemann IS, et al. Among authors: creasman w. Gynecol Oncol. 2023 Oct;177:38-45. doi: 10.1016/j.ygyno.2023.08.005. Epub 2023 Aug 25. Gynecol Oncol. 2023. PMID: 37634258 Free PMC article.
Letter to the Editor: 2023 FIGO staging system for endometrial cancer.
Raspagliesi F, Creasman W, Bogani G, Pecorelli S. Raspagliesi F, et al. Among authors: creasman w. Int J Gynaecol Obstet. 2024 Jan;164(1):366-368. doi: 10.1002/ijgo.15266. Epub 2023 Dec 6. Int J Gynaecol Obstet. 2024. PMID: 38055222 No abstract available.
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Hagemann IS, Deng W, Zaino RJ, Powell MA, Gunderson C, Cosgrove C, Mathews C, Pearl ML, Waggoner S, Ghebre R, Lele S, Guntupalli S, Secord AA, Ioffe O, Park K, Rasty G, Singh M, Soslow R, Creasman W, Mutch DG. Hagemann IS, et al. Among authors: creasman w. Gynecol Oncol. 2021 Mar;160(3):660-668. doi: 10.1016/j.ygyno.2020.12.040. Epub 2021 Jan 8. Gynecol Oncol. 2021. PMID: 33423806 Free PMC article.
Surgical training in gynecologic oncology: Past, present, future.
Hoffman MS, Chi DS, Clarke-Pearson DL, Cliby W, Creasman W, Underwood PB Jr. Hoffman MS, et al. Among authors: creasman w. Gynecol Oncol. 2020 Jul;158(1):188-193. doi: 10.1016/j.ygyno.2020.05.006. Epub 2020 May 23. Gynecol Oncol. 2020. PMID: 32456991 Review.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Vergote I, et al. Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7. Lancet Oncol. 2019. PMID: 31076365 Free article. Clinical Trial.
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS, Cohn DE, Brasky TM, Zaino R, Park K, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Randall ME, Brinton LA. Felix AS, et al. Among authors: creasman wt. Am J Obstet Gynecol. 2018 Nov;219(5):459.e1-459.e11. doi: 10.1016/j.ajog.2018.08.002. Epub 2018 Aug 7. Am J Obstet Gynecol. 2018. PMID: 30096321 Free PMC article.
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ. Cosgrove CM, et al. Among authors: creasman wt. Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11. Gynecol Oncol. 2018. PMID: 29132872 Free PMC article.
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel C, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA. Felix AS, et al. Among authors: creasman wt. Int J Cancer. 2018 Mar 15;142(6):1102-1115. doi: 10.1002/ijc.31127. Epub 2017 Nov 6. Int J Cancer. 2018. PMID: 29063589 Free PMC article.
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Devor EJ, et al. Among authors: creasman wt. Gynecol Oncol. 2017 Dec;147(3):648-653. doi: 10.1016/j.ygyno.2017.09.025. Epub 2017 Sep 29. Gynecol Oncol. 2017. PMID: 28969912 Free PMC article.
282 results